# DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

> **NCT03329690** · PHASE2 · COMPLETED · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 233 (actual)

## Conditions studied

- Neoplasm, Gastrointestinal

## Interventions

- **DRUG:** DS-8201a
- **DRUG:** Physician's Choice

## Key facts

- **NCT ID:** NCT03329690
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-02
- **Primary completion:** 2019-11-08
- **Final completion:** 2020-12-11
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2022-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03329690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03329690, "DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03329690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*